Suspension platform development for lentiviral vector manufacturing

Scroll Down

Development of a Transfection-based, Scalable, Serum-Free, Single-Use Suspension Platform for Manufacturing Lentiviral Vector

Lentiviral vectors (LVV) are commonly used to deliver genetic information into cells for gene expression for gene and cell therapies. However, clinical and commercial supply of cGMP LVV is under considerable global pressure due to limited scalability of adherent HEK293T cell line production systems.

Genezen has developed a new transfection-based, serum-free suspension platform to support LVV production in our upcoming GMP facility using a HEK293T-based suspension cell line: GL293T.

This new fully scalable GMP suspension platform enables efficient LVV manufacturing process with the benefit of a yield up to 4E7 TU/mL.

Download our poster presentation from ASGCT 2021 by completing the form to the right for further insight into how the new GL293T was developed and how it could be used in your next LVV project.

You may also be interested in...

Genezen Appoints Vice President of Quality…

Genezen Inc., a cell and gene therapy Contract Development and Manufacturing...

Read more

Get to know Genezen

Watch now Genezen is dedicated to exceptional gene and cell therapy....

Read more

Genezen Appoints New CEO as GMP…

Genezen Inc., a cell and gene therapy Contract Development and Manufacturing...

Read more

A time of flux: opportunities and…

In this blog, Katherine Moynihan, VP of Business Development and Marketing...

Read more